Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Averbuch

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
British Journal of Cancer|February 5, 2004
Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitorsG Blackledge, S Averbuch
Prostate Cancer and Prostatic Diseases|December 24, 2002
Anti-EGF receptor therapyG Blackledge, S Averbuch, A Kay, et al.
The American Journal of Occupational Therapy : Official Publication of the American Occupational Therapy Association|March 1, 1989
Loewenstein Occupational Therapy Cognitive Assessment (LOTCA) battery for brain-injured patients: reliability and validityN Katz, M Itzkovich, S Averbuch, et al.
Medical and Pediatric Oncology|January 1, 1994
Hypertensive crises induced by treatment of malignant pheochromocytoma with a combination of cyclophosphamide, vincristine, and dacarbazineL T Wu, P Dicpinigaitis, H Bruckner, et al.
The Annals of Thoracic Surgery|February 1, 1991
Nephrotic syndrome complicating adenocarcinoma of the lung with resolution after resectionW H Coltharp, S M Lee, R F Miller, et al.
Neurosurgery|July 1, 1990
Pheochromocytoma presenting as a skull metastasis with massive extracranial and intracranial extensionJ C Grabel, R I Gottesman, F Moore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2016
Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapyJ F Novotny, J Cogswell, H Inzunza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendationsB C Goh, M J Ratain, D Bertucci, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2004
Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumorsG Giaccone, J L González-Larriba, A T van Oosterom, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
British Journal of Cancer|February 5, 2004
Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitorsG Blackledge, S Averbuch
Prostate Cancer and Prostatic Diseases|December 24, 2002
Anti-EGF receptor therapyG Blackledge, S Averbuch, A Kay, et al.
The American Journal of Occupational Therapy : Official Publication of the American Occupational Therapy Association|March 1, 1989
Loewenstein Occupational Therapy Cognitive Assessment (LOTCA) battery for brain-injured patients: reliability and validityN Katz, M Itzkovich, S Averbuch, et al.
Medical and Pediatric Oncology|January 1, 1994
Hypertensive crises induced by treatment of malignant pheochromocytoma with a combination of cyclophosphamide, vincristine, and dacarbazineL T Wu, P Dicpinigaitis, H Bruckner, et al.
The Annals of Thoracic Surgery|February 1, 1991
Nephrotic syndrome complicating adenocarcinoma of the lung with resolution after resectionW H Coltharp, S M Lee, R F Miller, et al.
Neurosurgery|July 1, 1990
Pheochromocytoma presenting as a skull metastasis with massive extracranial and intracranial extensionJ C Grabel, R I Gottesman, F Moore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2016
Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapyJ F Novotny, J Cogswell, H Inzunza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendationsB C Goh, M J Ratain, D Bertucci, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2004
Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumorsG Giaccone, J L González-Larriba, A T van Oosterom, et al.
Pageof 1